Amgen Acquires Dark Blue Therapeutics for Up to $840 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy AMGN?
Source: NASDAQ.COM
- Acquisition Strategy: Amgen's acquisition of UK-based Dark Blue Therapeutics for up to $840 million enhances its research capabilities in acute myeloid leukemia (AML), further expanding its oncology product portfolio.
- Innovative Drug Development: This acquisition provides Amgen with an investigational small molecule that targets and degrades two proteins driving specific AML types, indicating potential in overcoming treatment resistance and enhancing remission durability.
- Preclinical Data Support: Promising anti-cancer activity and mechanistic differentiation from existing therapies have been demonstrated in leukemia models, suggesting new treatment options for both single-agent and combination therapies.
- Integration of R&D Resources: Amgen plans to integrate Dark Blue Therapeutics into its existing research organization, thereby strengthening its early oncology discovery efforts and enhancing its competitive position in the rapidly evolving cancer treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 366.210
Low
280.00
Averages
363.10
High
425.00
Current: 366.210
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Amgen and GSK Join TrumpRx Drug Sales Platform
- Expansion of Drug Sales: Amgen (AMGN) and GSK (GSK) are adding their medications to the TrumpRx platform, bringing the total to 54 prescription drugs available, marking a significant step in the government's push for drug affordability.
- Significant Price Discounts: Amgen plans to offer Amjevita at $299 on TrumpRx, a staggering 80% reduction from its current U.S. list price of $1,484; additionally, Aimovig and Repatha will also see around 60% discounts, greatly enhancing consumer purchasing power.
- GSK Drug Discounts: GSK's Incruse for chronic obstructive pulmonary disease will be priced at $159 on TrumpRx, reflecting a 55% discount; furthermore, other medications like Arnuity, Relenza, and Anoro will have discounts ranging from 10% to 51%, boosting market competitiveness.
- Far-reaching Policy Impact: The inclusion of Amgen and GSK not only diversifies the drug offerings on TrumpRx but also underscores the Trump administration's firm stance on drug pricing policies, aiming to enhance drug accessibility through Most Favored Nation pricing.
See More
GSK and Amgen Expand TrumpRx with New Medications - Fox Business
Prescription Drug Makers: Pharmaceutical companies are facing scrutiny for their role in the opioid crisis and the impact of their medications on public health.
Legal and Financial Consequences: Many drug manufacturers are dealing with lawsuits and financial penalties related to their marketing practices and the addictive nature of their products.
Regulatory Changes: There is a push for stricter regulations and oversight on prescription drugs to prevent misuse and ensure patient safety.
Public Health Initiatives: Efforts are being made to educate the public about the risks associated with prescription medications and to promote alternative pain management strategies.
See More
Income Fund Excels Thanks to Stocks Like Starbucks, Amgen, and CVS
- Hilda Applbaum's Passion: Hilda Applbaum, a resident of Oakland, California, takes great pride in her blueberry bushes.
- Gardening Joy: She enjoys the process of planting seedlings, nurturing their growth, and harvesting the berries for her morning yogurt.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Amgen and GSK Join TrumpRx Drug Sales Platform
- Expansion of Drug Sales: Amgen (AMGN) and GSK (GSK) are adding their medications to the TrumpRx platform, bringing the total to 54 prescription drugs available, marking a significant step in the government's push for drug affordability.
- Significant Price Discounts: Amgen plans to offer Amjevita at $299 on TrumpRx, a staggering 80% reduction from its current U.S. list price of $1,484; additionally, Aimovig and Repatha will also see around 60% discounts, greatly enhancing consumer purchasing power.
- GSK Drug Discounts: GSK's Incruse for chronic obstructive pulmonary disease will be priced at $159 on TrumpRx, reflecting a 55% discount; furthermore, other medications like Arnuity, Relenza, and Anoro will have discounts ranging from 10% to 51%, boosting market competitiveness.
- Far-reaching Policy Impact: The inclusion of Amgen and GSK not only diversifies the drug offerings on TrumpRx but also underscores the Trump administration's firm stance on drug pricing policies, aiming to enhance drug accessibility through Most Favored Nation pricing.
See More
GSK and Amgen Expand TrumpRx with New Medications - Fox Business
Prescription Drug Makers: Pharmaceutical companies are facing scrutiny for their role in the opioid crisis and the impact of their medications on public health.
Legal and Financial Consequences: Many drug manufacturers are dealing with lawsuits and financial penalties related to their marketing practices and the addictive nature of their products.
Regulatory Changes: There is a push for stricter regulations and oversight on prescription drugs to prevent misuse and ensure patient safety.
Public Health Initiatives: Efforts are being made to educate the public about the risks associated with prescription medications and to promote alternative pain management strategies.
See More
Income Fund Excels Thanks to Stocks Like Starbucks, Amgen, and CVS
- Hilda Applbaum's Passion: Hilda Applbaum, a resident of Oakland, California, takes great pride in her blueberry bushes.
- Gardening Joy: She enjoys the process of planting seedlings, nurturing their growth, and harvesting the berries for her morning yogurt.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
